{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:23:26Z","timestamp":1792887806690,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012446","name":"Oslo University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ejpn-journal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejpn.2024.09.009","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T13:25:22Z","timestamp":1728566722000},"page":"109-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Type 1 spinal muscular atrophy treated with nusinersen in Norway, a five-year follow-up"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3609-8219","authenticated-orcid":false,"given":"Merete","family":"Wik-Klokk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnhild","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"\u00d8rstavik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milada","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9827-553X","authenticated-orcid":false,"given":"Marie Elizabeth","family":"Holtebekk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Ramm-Pettersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejpn.2024.09.009_bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"1","key":"10.1016\/j.ejpn.2024.09.009_bib2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","article-title":"Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2","volume":"4","author":"Mailman","year":"2002","journal-title":"Genet. Med."},{"issue":"6","key":"10.1016\/j.ejpn.2024.09.009_bib3","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/MOP.0b013e32833f3046","article-title":"Spinal muscular atrophy: a time for screening","volume":"22","author":"Prior","year":"2010","journal-title":"Curr. Opin. Pediatr."},{"issue":"18","key":"10.1016\/j.ejpn.2024.09.009_bib4","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ejpn.2024.09.009_bib5","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ejpn.2024.09.009_bib6","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jnnp-2017-317412","article-title":"Nusinersen for SMA: expanded access programme","volume":"89","author":"Farrar","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.ejpn.2024.09.009_bib7","doi-asserted-by":"crossref","first-page":"fcac269","DOI":"10.1093\/braincomms\/fcac269","article-title":"Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study","volume":"4","author":"Scheijmans","year":"2022","journal-title":"Brain Commun"},{"issue":"2","key":"10.1016\/j.ejpn.2024.09.009_bib8","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/brain\/awac252","article-title":"Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy","volume":"146","author":"Pechmann","year":"2023","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.ejpn.2024.09.009_bib9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nmd.2022.02.001","article-title":"Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland","volume":"32","author":"Tscherter","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ejpn.2024.09.009_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"15_supplement","key":"10.1016\/j.ejpn.2024.09.009_bib11","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.94.15_supplement.1640","article-title":"Nusinersen in infantile-onset spinal muscular atrophy:Results from longer-term treatment from the open-label SHINE extension study (1640)","volume":"94","author":"Castro","year":"2020","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ejpn.2024.09.009_bib12","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/ene.15768","article-title":"Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function","volume":"30","author":"Pane","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejpn.2024.09.009_bib13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejpn.2024.06.004","article-title":"An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies","volume":"51","author":"Giess","year":"2024","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"9","key":"10.1016\/j.ejpn.2024.09.009_bib14","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","article-title":"NFL is a marker of treatment response in children with SMA treated with nusinersen","volume":"266","author":"Olsson","year":"2019","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2024.09.009_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The children's hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul. Disord."},{"issue":"23","key":"10.1016\/j.ejpn.2024.09.009_bib16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/PEP.0b013e3182351f04","article-title":"Validation of the Children's hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND)","author":"Glanzman","year":"2011","journal-title":"Pediatr. Phys. Ther."},{"issue":"9\u201310","key":"10.1016\/j.ejpn.2024.09.009_bib17","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the Hammersmith functional motor Scale for SMA II and III patients","volume":"17","author":"O'Hagen","year":"2007","journal-title":"Neuromuscul. Disord."},{"issue":"2 Pt 1","key":"10.1016\/j.ejpn.2024.09.009_bib18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0022-3476(99)70016-8","article-title":"Optimality score for the neurologic examination of the infant at 12 and 18 months of age","volume":"135","author":"Haataja","year":"1999","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ejpn.2024.09.009_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.braindev.2023.07.005","article-title":"Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen","author":"Seo","year":"2023","journal-title":"Brain Dev."},{"issue":"1","key":"10.1016\/j.ejpn.2024.09.009_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13195-018-0339-1","article-title":"A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation","volume":"10","author":"Gaetani","year":"2018","journal-title":"Alzheimer's Res. Ther."},{"issue":"2","key":"10.1016\/j.ejpn.2024.09.009_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejpn.2024.09.009_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00207454.2023.2251662","article-title":"Safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 524 patients: results from an interim analysis of post-marketing surveillance in Japan","author":"Tachibana","year":"2023","journal-title":"Int. J. Neurosci."},{"issue":"12","key":"10.1016\/j.ejpn.2024.09.009_bib23","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial","volume":"21","author":"Masson","year":"2022","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.ejpn.2024.09.009_bib24","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/acn3.51449","article-title":"Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children","volume":"8","author":"Nitz","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2024.09.009_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","article-title":"Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years","volume":"16","author":"Vill","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ejpn.2024.09.009_bib26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41436-020-00987-w","article-title":"CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening","volume":"23","author":"Weng","year":"2021","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ejpn.2024.09.009_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3233\/JND-221671","article-title":"Monitoring nusinersen treatment effects in children with spinal muscular atrophy with quantitative muscle MRI","volume":"11","author":"Otto","year":"2024","journal-title":"J. Neuromuscul. Dis."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379824001521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379824001521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T01:09:27Z","timestamp":1732928967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379824001521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":27,"alternative-id":["S1090379824001521"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.09.009","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type 1 spinal muscular atrophy treated with nusinersen in Norway, a five-year follow-up","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}